The firms hope to show that Verdi's off-the-shelf peptide cancer vaccine can shrink tumors and improve quality of life in patients with bone metastases.

Anixa Biosciences (NASDAQ:ANIX – Get Free Report)‘s stock had its “buy” rating reaffirmed by equities researchers at HC ...

Anixa Biosciences signed a letter of intent with VERDI Solutions to develop AI-powered personalized and off-the-shelf cancer ...

Anixa Biosciences secured a USPTO patent allowance for its ovarian cancer vaccine, strengthening its IP position and ...

Fintel reports that on March 21, 2025, Maxim Group initiated coverage of Anixa Biosciences (NasdaqCM:ANIX) with a Buy ...

Anixa Biosciences Receives Notice of Allowance from USPTO for Ovarian Cancer Vaccine. Anixa Biosciences, Inc. March 24, 2025.

Anixa Biosciences inks LoI with VERDI Solutions to develop artificial intelligence-guided personalized and off-the-shelf peptide vaccines for cancer: San Jose, Calif Friday, March ...

Anixa Biosciences (ANIX) has entered into a letter of intent with Verdi Solutions to develop personalized and off-the-shelf peptide vaccines ...

D. Boral Capital restated their buy rating on shares of Anixa Biosciences (NASDAQ:ANIX – Free Report) in a report released on Wednesday,Benzinga reports. They currently have a $10.00 price ...

The CAGLA NeauxCancer Conference is a premier gathering of leading oncology researchers, industry executives, investors and medical professionals focused on groundbreaking developments in cancer ...

SAN JOSE, Calif., March 24, 2025 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today ...